# Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3

> **NCT05923177** · PHASE1 · COMPLETED · sponsor: **Tomsk National Research Medical Center of the Russian Academy of Sciences** · enrollment: 10 (actual)

## Conditions studied

- Primary Breast Cancer

## Interventions

- **DRUG:** SPECT

## Key facts

- **NCT ID:** NCT05923177
- **Lead sponsor:** Tomsk National Research Medical Center of the Russian Academy of Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923177, "Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05923177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*